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Summary
 
Superantigens encoded by the mouse mammary tumor virus can stimulate a large proportion of
T cells through interaction with germline-encoded regions of the T cell receptor 
 
b
 
 chain like
the hypervariable region 4 (HV4) loop. However, several lines of evidence suggest that somat-
ically generated determinants in the CDR3 region might influence superantigen responses. We
stimulated T cells from donors differing at the BV6S7 allele with vSAG9 to assess the nature
and structure of the T cell receptor in amplified T cells and to evaluate the contribution of
non-HV4 elements in vSAG recognition. This report demonstrates that vSAG9 stimulation
caused the expansion of TCR BV6-expressing T cells, although to varying degrees depending
on the BV6 subfamily. The BV6S7 subfamily was preferentially expanded in all donors, but in
 
donors homozygous for the BV6S7
 
*
 
2 allele, a significant number of BV6S5 T cells were ampli-
fied and showed a highly biased 
 
b
 
 chain junctional region (BJ) and CDR3 usage. As CDR3 re-
gions are involved in major histocompatibility complex (MHC)–peptide interaction, such a se-
lection is highly suggestive of an intimate MHC–TCR interaction and would imply that the
topology of the MHC-vSAG-TCR complex is similar to the one occurring during conven-
tional antigen recognition.
 
M
 
ouse mammary tumor virus (MMTV) is a retrovirus
that uses the immune system for its transmission by
encoding a viral superantigen (vSAG) (1). MMTV vSAGs
can stimulate a large pool of T cells by interacting with the
hypervariable region 4 (HV4) of the TCR 
 
b
 
 chain, which
is germline encoded by individual 
 
b
 
 chains (2, 3) and is dis-
tinct from the CDR3 hypervariable region involved in rec-
ognition of antigens presented by MHC molecules (4). Since
SAG-responsive cells can express different TCR 
 
a
 
 and 
 
b
 
combinations, it is believed that an intimate TCR–MHC
interaction is not required for recognition, as most T cells
bearing appropriate 
 
b
 
 chain variable regions (BVs) can re-
spond to vSAGs (1). Potential contributions of non-HV4
elements have been proposed since vSAG response can be
influenced by 
 
a
 
 chain usage (5, 6), and nonrandom joining
region usage has been described in SAG-responsive BVs
(7). T cell repertoire analysis in mice differing by the pres-
ence of vSAG7 has shown that particular 
 
b
 
 chain junctional
regions (BJs) and CDR3 lengths were underrepresented in
BVs having survived deletion (8), but this indirectly infers a
CDR3 selection by analyzing the structure of TCRs in
nonresponding cells. These data suggest that TCR–MHC
contacts might be required for productive interaction. To
assess which TCRs would be amplified by vSAG stimula-
tion, we subjected T cells from individuals, differing at the
BV6S7 allele, to vSAG9 stimulation. The structure of
TCRs amplified by vSAG9 provides evidence that CDR3s
are selected in BVs having lower responsiveness towards
the superantigen. This suggests that additional contacts pro-
vided by CDR3–peptide interaction allow stabilization of
the complex and implies that vSAGs cross-link MHC and
TCR in a way that preserves interactions seen in conven-
tional antigen recognition (4, 9), in marked contrast with
what occurs during bacterial SAG (bSAG) recognition (10).
 
Materials and Methods
 
Genotyping for BV6S7 Alleles.
 
The nomenclature used for BV
genes is according to Wei et al. (11). PBMCs were separated by
Ficoll centrifugation (Pharmacia Biotech AB, Uppsala, Sweden)
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and stimulated for 24 h with 1 
 
m
 
g/ml of PHA (Murex Diagnos-
tics, Guelph, Canada). Total RNA was extracted from 4 
 
3
 
 10
 
7
 
cells with RNAzol B (CINNA/BIOTECX Laboratories, Hous-
ton, TX) and 10 
 
m
 
g were reverse transcribed with 5 
 
m
 
g of oli-
godT and 60 U of AMV-RT (Life Sciences, St. Petersburg, FL).
The BV6S7 cDNAs were amplified by PCR using primers and
conditions described elsewhere (12), digested with BamHI, and
fractionated on 2% gels.
 
T Cell Stimulation with vSAG9.
 
Human T cells were purified
from four donors homozygous for either BV6S7 allele using ro-
setting with sheep red blood cells (Quélab, Montréal, Canada)
and PBMCs separated by Ficoll centrifugation. Purity was assessed
by staining with anti-CD3 (OKT3-FITC) and anti–HLA-DR
(L-243) mAbs (Becton Dickinson, Mountain View, CA) and T
cell purity was 
 
.
 
99%, whereas the non–T cell fraction contained
 
,
 
15% of T cells. T cells were stimulated in the presence of irradi-
ated autologous feeder cells with DAP-DR1 cells, which are mu-
rine fibroblasts transfected with DR1 
 
a
 
 and 
 
b
 
 chain cDNAs, or
DAP-DR1 expressing vSAG9 (13). DAP-DR1 and DR1-vSAG9
cells were treated for 1 h at 37
 
8
 
C with 100 
 
m
 
g/ml mitomycin C
(Sigma Chemical Co., St. Louis, MO) and cocultured in 96-well
plates in DMEM, 5% FCS, 2 mM 
 
l
 
-glutamine, and 20 
 
m
 
g/ml
gentamycin. 6 
 
3
 
 10
 
5
 
 human T cells were cultured with 2 
 
3
 
 10
 
5
 
DAP-DR1 or DR1-SAG9 in the presence of 5 
 
3
 
 10
 
5
 
 autologous
irradiated feeder cells. After 2 d, 10 U/ml of recombinant human
IL-2 was added and the culture proceeded for an additional 7 d.
For PHA stimulation, 10
 
6
 
 T cells were cocultured in 24-well
plates with 2 
 
3
 
 10
 
5
 
 irradiated feeder cells and 1 
 
m
 
g/ml PHA in
1.5 ml. Proliferation was measured by [
 
3
 
H]thymidine incorpora-
tion (Dupont Co.–New England Nuclear, Boston, MA) after 3 d
and determined with a 
 
b
 
 plate counter (Pharmacia Biotech AB).
 
FACS
 
Ò
 
 and Quantitative PCR Analysis of the BV Repertoire.
 
FACS
 
Ò
 
 analysis was performed after T cell stimulation with
DR1-SAG9 or PHA, using CD4, CD8, and BV-specific mAbs.
The BV-specific mAbs used were anti-BV2, 3, 8, BV13S3
(JU74), 17, 19, 21 (Immunotech Coulter, St. Laurent, Canada),
BV5 (MH3-2), BV5 (3D11), BV6S7
 
*
 
1 (OT145), BV9 (MKB1),
BV12 (S511), BV13 (BAMB), BV13S1 (H131), BV13S2 (H132),
and BV23 (HUT-78). Cells were stained for CD4 (OKT4-PE)
and CD8 (OKT8-PerCP) (Becton Dickinson) and 3 
 
3
 
 10
 
5
 
 live
cells were gated according to forward and side light scatter and
analyzed on a FACScan
 
Ò
 
. For quantitative PCR (qPCR), cDNAs
were synthesized as described above and PCR was performed us-
ing conditions and primers described elsewhere (14). PCR prod-
ucts were fractionated on 12% polyacrylamide gels and exposed
overnight on PhosphorImager screens (Molecular Dynamics, Sun-
nyvale, CA). Quantification of signals was performed on a Phos-
phorImager running the IMAGEQUANT software (Molecular
Dynamics) and normalized against a TCR 
 
a
 
 chain constant re-
gion internal control (14).
 
Cloning and Analysis of BV6 Subfamily Members.
 
BV6 mem-
bers were amplified by PCR using DeepVent (New England
Biolabs, Mississauga, Canada) using the constant region primer GGT-
GTGGGAGATGTCGACTTTTGATGGCTCAAAC and the
pan-BV6 primer: CCTTTACTGGTACCGACAGAGCCTGG.
PCR products were digested with KpnI and SalI, cloned into
pBSKS
 
1
 
 (Stratagene, La Jolla, CA), and recombinants were
screened by PCR using reverse and universal primers (15). BV6
members were subdivided by RFLP based on the presence of
BamHI and ApaLI sites (BamHI
 
1
 
ApaLI
 
1
 
: BV6S7
 
*
 
1; BamHI
 
2
 
ApaLI
 
1
 
: BV6S7
 
*
 
2; BamHI
 
2
 
ApaLI
 
2
 
: BV6S5; BamHI
 
1
 
ApaLI
 
2
 
:
BV6S1, BV6S3, BV6S4, BV6S11, and BV6S14). 10 
 
m
 
l of PCR
reactions were digested with BamHI and ApaLI and fractionated
on 2% gels. Sequence determination was performed using the T7
Sequencing Kit (Pharmacia Biotech AB).
 
Results and Discussion
 
Since vSAG9 can stimulate BV6S7
 
1
 
 human T cells and
polymorphism between BV6S7 alleles is located within the
HV4 region (16), we assumed that responsiveness to
vSAG9 might differ between individuals homozygous for
either allele and that analysis of BVs expanded in donors
bearing a less responsive allele might reveal the contribu-
tion of non-HV4 elements in vSAG9 response.
 
vSAG9 Preferentially Expands the TCR BV6 Family.
 
Since the murine cell line DAP, expressing both HLA-
DR1 (DAP-DR1) and vSAG7, has been shown to stimu-
late human T cells in a BV-restricted manner (14), we used
DAP-DR1 transfected with vSAG9 (DR1-SAG9; refer-
ence 13) to stimulate T cells from an individual homozy-
gous for BV6S7
 
*
 
1 (donor J). Proliferation measured by
thymidine incorporation peaked after 4 d of coculture and
was reproducibly fourfold higher compared to control DR1
cells (data not shown). FACS
 
Ò
 
 analysis of BV usage in hu-
man CD4
 
1
 
 T cells in response to vSAG9 or PHA, a mito-
gen that stimulates T cells independently of BV usage (17 and
data not shown), shows that vSAG9 stimulated BV6S7
 
*
 
1
 
1
 
and BV21
 
1
 
 T cells (Fig. 1 
 
A
 
). Since the BV-specific mAbs
currently available cover 
 
z
 
65% of the repertoire, qPCR
analysis was performed and this confirmed that only BV6
and BV21 responded to vSAG9 and were amplified four-
and threefold, respectively (Fig. 1 
 
B
 
). This selective expan-
sion was reproduced on a second BV6S7
 
*
 
1 homozygous
individual (data not shown). T cells derived from two indi-
viduals homozygous for the BV6S7
 
*
 
2 allele (donors S and
M) were stimulated with vSAG9 and proliferation was six-
and fourfold higher compared to control DAP-DR1 cells
(data not shown). Quantitative PCR analysis was per-
formed and, as with the BV6S7
 
*
 
1 donors, only BV6
 
1
 
 and
BV21
 
1
 
 T cells were amplified (Fig. 2, 
 
A
 
 and 
 
B
 
). The re-
sponsiveness of BV6 and BV21 is not surprising given that
they share significant homology, notably in the CDR1 and
HV4 regions (18). HLA typing for MHC haplotypes was
performed and showed that donor J was DR1/DR1, donor
S was DR7/DR7, and donor M was DR2/DR7. Al-
though donors S and M express MHC molecules different
from DR1, T cell proliferation after 3 d of coculture with
the control DR1 transfectant was similar between the DR1
donor (3.2 
 
3
 
 10
 
4
 
 cpm) and the non-DR1 donors (3.1 
 
3
 
10
 
4
 
 and 3.0 
 
3
 
 10
 
4
 
 cpm), indicating that no significant allo-
geneic response occurred, which is not surprising since
DAP cells are known to be poor at eliciting alloresponses
(19). From qPCR analysis, it is apparent that the over-
whelming majority of T cells that responded to vSAG9 be-
longed to the BV6 family (Figs. 1 
 
B
 
, 2, 
 
A
 
 and 
 
B
 
). Since the
human BV6 locus contains seven expressed genes (18) and
our qPCR did not allow discrimination between subfamily
members, BV6s were amplified using a pan-BV6 primer
and cloned for analysis. Approximately 200 clones from
PHA- and vSAG9-stimulated cells were analyzed by 
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RFLP. For donor J (BV6S7
 
*
 
1 homozygous), 98% of the
clones obtained after vSAG9 stimulation used BV6S7. With
donors S and M (BV6S7
 
*
 
2 homozygous), RFLP analysis
showed that 64 and 87% of the clones used BV6S7, al-
though a significant number of other BV6 gene segments
were also obtained after stimulation (Table 1). For donor S,
27% of the BV6s present after vSAG9 stimulation were
BV6S5
 
1
 
, whereas in donor M, 5% of BV6 gene segments
were BV6S5
 
1
 
. For all donors, BV6S7 was clearly the best
responder to vSAG9, as evidenced by the low numbers of
BV6
 
1
 
, non-BV6S7 cells present after stimulation. For do-
nor M, the proportion of BV6S7
 
*
 
2-positive clones present
in the PHA-stimulated population was twice that of the
other donors (Table 1) and appear to have dominated the
vSAG9 response, perhaps explaining the lower number of
BV6S5 found after stimulation.
 
CDR3 Structure of BV6 Subfamily Members Amplified by
vSAG9.
 
To evaluate the possible contribution of the 
 
b
 
chain CDR3 in recognition of the vSAG9–MHC com-
plex, TCR junctional regions from T cells stimulated by
vSAG9 or PHA were sequenced. Sequence analysis of the
BV6S7 clones revealed no particular BJ selection from ei-
ther vSAG9- or PHA-stimulated cells, with a random BJ
usage and CDR3 length distribution (data not shown, Ta-
ble 2). In contrast, the BV6S5 clones obtained after vSAG9
stimulation in donor S revealed a striking bias; 89% of
Figure 1. (A) Cytofluorometric analysis of TCR BV usage in T cells
stimulated by vSAG9. T cells from donor J (homozygous for BV6S7*1)
were stained with a panel of human BV-specific antibodies. Shown is the
percentage of BV expression in CD41 T cells after PHA, DR1, or
vSAG9 stimulation. (B) Percentage of TCR BV usage determined by
qPCR analysis. The signal intensity for each BV obtained by volume in-
tegration using the IMAGEQUANT software was normalized against the
a chain internal control, and the relative percentage of BV expression was
calculated by dividing the individual normalized values by the sum of all
BV normalized values.
Figure 2. qPCR analysis of TCR BV usage in vSAG9-stimulated T
cells from BV6S7*2 donors. (A) Donor S, homozygous for the BV6S7*2
allele; (B) donor M, homozygous for the BV6S7*2 allele. The values were
calculated as described in the legend of Fig. 1 B.
Table 1. Percentage of BV6 Subfamily Members Assessed by 
RFLP Analysis
PHA vSAG9
Donor
BV-
6S7
BV-
6S5
BV6S1,
S3, S4,
S11, S14
BV-
6S7
BV-
6S5
BV6S1,
S3, S4,
S11, S14
J (BV6S7*1) 21 69 10 98 0 2
S (BV6S7*2) 17 68 15 64 27 9
M (BV6S7*2) 42 43 15 87 5 8
Donor J PHA n 5 200 clones, vSAG9, n 5 200 clones; donor S PHA
n 5 194 clones, vSAG9 n 5 198 clones; donor M PHA n 5 143
clones, vSAG9 n 5 143 clones.256 TCR CDR3 Bias during vSAG9 Response
BV6S5 clones amplified used the BJ1S5 element (Table 2),
whereas BJ1S5 usage in BV6S5 clones from PHA-stimu-
lated T cells was not elevated (10%; data not shown). Two
dominant clonotypes were found, with CDR3 regions bear-
ing a P(Q/E)NSG motif (Table 2), created entirely by
N-additions at the V–J junction. In donor M, a dominant
BV6S5 clonotype, having the totally N-encoded CDR3
region, LEHSTRP, represented 89% of the BV6S51 clones
present after vSAG9 stimulation (Table 2), whereas this
clonotype could not be detected in PHA-stimulated cells
(data not shown). The number of BV6S1, S3, and S4
present after vSAG9 stimulation was low in all donors, and
Table 2. Junctional Regions of BV6s from vSAG9-stimulated Cells of Donors S and M
Donor S Donor M
BV N-D-N BJ n* BV N-D-N BJ n*
6S5 CASS LPTGGVED TIYFG 1S3 1/18 6S5 CASS FPSGGL YEQYFG 2S7 1/9
6S5 CASS SLNSG NQPQHFG 1S5 1/18 6S5 CASS LEHSTRP YEQYFG 2S7 8/9
6S5 CASS PQNSG NQPQHFG 1S5 9/18
6S5 CASS PENSG NQPQHFG 1S5 4/18 6S7*2 CASS YRVG EKLFFG 1S4 1/25
6S5 CASS PNSG NQPQHFG 1S5 1/18 6S7*2 CASS LVGTTDQG KLFFG 1S4 1/25
6S5 CASS WGLAW NEQFFG 2S1 1/18 6S7*2 CASS LDGRN NSPLHFG 1S6 1/25
6S5 CASS LDRGS EQFGG 2S1 1/18 6S7*2 CASS QDTS SYNEQFFG 2S1 1/25
6S7*2 CASS PGAGGPP YNEQFFG 2S1 1/25
6S7*2 CASS LNQLKH TEAFFG 1S1 1/22 6S7*2 CASS KGGAGP YNEQFFG 2S1 1/25
6S7*2 CASS LSAGTI EAFFG 1S1 1/22 6S7*2 CASS WRGSSTN NEQFFG 2S1 1/25
6S7*2 CASS LTRD YGYTFG 1S2 1/22 6S7*2 CASS LVAGGQ NEQFFG 2S1 1/25
6S7*2 CASS LTRGA GNTIYFG 1S3 1/22 6S7*2 CASS AGTSGGG EQFFG 2S1 1/25
6S7*2 CASS RPEGQYR NTIYFG 1S3 1/22 6S7*2 CASS LLPFQ QFFG 2S1 1/25
6S7*2 CASS TQTG QPQHFG 1S5 1/22 6S7*2 CASS YKGGGPT TDTQYFG 2S3 1/25
6S7*2 CASS LQWGG NSPLHFG 1S6 1/22 6S7*2 CASS SRFVAGG TDTQYFG 2S3 1/25
6S7*2 CASS LANGGIG SPLHFG 1S6 1/22 6S7*2 CASS FRSVG TDTQYFG 2S3 1/25
6S7*2 CASS RALLREQD SYNEQFFG 2S1 1/22 6S7*2 CASS PFSSR TDTQYFG 2S3 1/25
6S7*2 CASS YQS YNEQFFG 2S1 1/22 6S7*2 CASS SRGFR TDTQYFG 2S3 1/25
6S7*2 CASS LTGRVN NEQFFG 2S1 1/22 6S7*2 CASS PRGSGR DTQYFG 2S3 1/25
6S7*2 CASS SEYVTI EQFFG 2S1 1/22 6S7*2 CASS STVV DTQYFG 2S3 1/25
6S7*2 CASS SGTSS EQFFG 2S1 1/22 6S7*2 CASS SMGR QETQYFG 2S5 1/25
6S7*2 CASS QGGGQA GELFFG 2S2 1/22 6S7*2 CASS LTLGGY ETQYFG 2S5 1/25
6S7*2 CASS PRFI TDTQYFG 2S3 1/22 6S7*2 CASS ARRV ETQYFG 2S5 1/25
6S7*2 CASS SRLVTLGS FG 2S3 1/22 6S7*2 CASS SDH YEQYFG 2S7 1/25
6S7*2 CASS SGLAGV AKNIQYFG 2S4 1/22 6S7*2 CASS GT YEQYFG 2S7 1/25
6S7*2 CASS LAPRD YEQYFG 2S7 1/22 6S7*2 CASS LSLGSS EQYFG 2S7 1/25
6S7*2 CASS FMDT YEQYFG 2S7 1/22 6S7*2 CASS QTV EQYFG 2S7 1/25
6S7*2 CASS AGLALR EQYFG 2S7 1/22 6S7*2 CASS QP YFG 2S7 1/25
6S7*2 CASS FGGSG QYFG 2S7 1/22
6S1 CASS GG TDTQYFG 2S3 2/9
6S1 CASS LFKG SYNEQFFG 2S1 1/7 6S3 CASS EGQGASD EQFFG 2S1 1/9
6S1 CASS YRDTF SGANVLTFG 2S6 1/7 6S4 CASS PERL SGNTIYFG 1S3 1/9
6S3 CASS LIGG SYEQYFG 2S7 1/7 6S4 CAST LRTGN NEQFFG 2S1 1/9
6S3 CASS TSRST EQYFG 2S7 1/7 6S4 CASS LTSGRAR DTQYFG 2S3 1/9
6S4 CASS LESTGAR NTIYFG 1S3 1/7 6S4 CASS GARGSGE QETQYFG 2S5 1/9
6S4 CASS HKGG TGELFFG 2S2 1/7 6S4 CASS LGR ETQYFG 2S5 1/9
6S4 CASS LAAGA DTQYFG 2S3 1/7 6S4 CASS PQEGG YEQYFG 2S7 1/9
*n, the number of times a given sequence was found. The sequences data are available from EMBL/GenBank/DDBJ under accession numbers
AF011574–AF011643.257 Ciurli et al. Brief Definitive Report
the total lack of CDR3 bias seen in these clones suggests
that they have not been amplified. Thus, the bias observed
in the CDR3 region of BV6S5 clones suggests that inti-
mate MHC–TCR contacts might exist during vSAG re-
sponse. Other studies have yielded similar results, as se-
quence analysis of TCR-b junctional regions in BV61
CD41 T cells that survived deletion mediated by vSAG7
showed a BJ usage and CDR3 length distribution that dif-
fered significantly from H2-matched mice lacking vSAG7
(8). Introduction of an Ea transgene in SJL mice, which do
not express I-E and therefore can not present the endoge-
nous vSAG9, restores deletion of BV171 T cells; when
compared to nontransgenic mice, T cells having survived
negative selection showed increased BJ2S5 and decreased
BJ1S1 usage, indicating that the nature of the BJ segment
can have an impact on T cell deletion (7). Our results are in
agreement with these studies and extend them by provid-
ing evidence that the structure of the CDR3 plays a posi-
tive role in vSAG responsiveness.
Model of MHC-vSAG-TCR Interaction. Comparison of
HV4 sequences between BV6s and BV21s reveals that they
are highly homologous except for the presence of a glu-
tamic acid at the tip of the HV4 loop in all nonresponding
BV6s. The allelic polymorphism between the BV6S7s is lo-
cated next to that residue in which the glycine present in
BV6S7*1 is replaced by a glutamic acid in BV6S7*2. These
differences might partially explain the differential reactivity
observed between BV6 subfamily members. Although HV4
is clearly the overriding determinant in vSAG recognition,
it appears that a BV with a suboptimal HV4 would become
more dependent on stabilization provided by TCR–MHC
contacts. As mutagenesis of the CDR1 in murine BV6 was
shown to abrogate both vSAG7 and conventional antigen
recognition (20), this argues in favor of a similar MHC–
TCR topology. In addition, mutagenesis in CDR1 (but
not CDR2) affects vSAG responsiveness, and mutagenesis
in CDR2 (but not CDR1) affects bSAG reactivity, indicat-
ing that vSAGs and bSAGs probably bind differently to the
TCR (21). Mutagenesis studies have shown the importance
of CDR2 in bSAG recognition (21, 22) and the structure
of SEC3 bound to TCR shows that it contacts the CDR2
peptide backbone and should act like a wedge between
TCR and MHC, allowing only part of the MHC to con-
tact the TCR (10). In addition, the structure of SEB bound
to DR1 predicts that the SAG-MHC-TCR orientation
should differ by 458 compared to MHC-peptide-TCR ori-
entation (23).
Our results and those from others (7, 8) indicate that BJ
usage impacts vSAG recognition. Although this region might
be a contact site for vSAGs, we feel this is unlikely given
it is located opposite to HV4 (4, 9) and that the two
BV6S7*2 homozygous individuals used different BJs. The
BJ bias observed during vSAG9 response might be due to a
TCR interaction with a peptide present in the MHC groove,
since the BJ gene segment contributes for a significant por-
tion of the CDR3 (4, 9). The different CDR3s found in
the two donors could be due to recognition of different
peptides or a dominant peptide being recognized by both
TCRs, since TCRs having identical BV segments, but dif-
ferent CDR3 sequences, can recognize the same peptide–
MHC complex (24). Since the TCR a and b chains CDR1
and CDR2 are involved in MHC contacts (4), this would
explain a chain biases (5, 6) and the contribution of the b
chain CDR1 (20, 21), whereas the skewed BJ usage ob-
served (7, 8) could be explained by CDR3 contacts with
peptide–MHC complexes. Thus, the data in the literature
about the role of non-HV4 regions in vSAG responses
could be readily reconciled using a model in which vSAGs
cross-link MHC and TCR in a way that allows the interac-
tions occurring during conventional antigen recognition to
exist.
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